Bayer AG Stock
€36.46
Your prediction
Description Bayer
Bayer AG, listed on the Frankfurt Stock Exchange with the symbol BAYN and on the OTC market in the US with the symbol BAYZF, is a German multinational pharmaceutical and life sciences company. With its headquarters in Leverkusen, Germany, the company is one of the leading companies in the fields of healthcare, agriculture, and high-tech polymer materials.
Bayer's activities in healthcare include the development, production, and sale of innovative medicines, including prescription drugs and over-the-counter drugs, as well as medical devices, diagnostic equipment, and veterinary products. The company offers products across various therapeutic areas such as cardiology, oncology, hematology, ophthalmology, and women's health. Additionally, in agriculture, Bayer is involved in crop protection, seeds and traits, and digital farming solutions.
In recent years, Bayer has faced numerous legal challenges associated with its acquisition of Monsanto, a controversial US-based agrochemical and biotechnology company. Some of these challenges have included lawsuits and allegations regarding the safety of Monsanto's glyphosate-based herbicides and their potential link to cancer.
As of August 2021, Bayer had a market capitalization of approximately 53 billion euros and was ranked among the largest 30 companies on the Frankfurt Stock Exchange.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of Bayer
As a global pharmaceutical and life sciences company, Bayer (Symbol BAYZF) faces several key competitors across its various business segments. Here are some of the most important competitors that pose a significant threat to Bayer:
1. Johnson Johnson (JNJ): This US-based healthcare giant competes with Bayer in the pharmaceutical and medical devices space, particularly in the areas of cardiovascular, immunology, and oncology. Johnson Johnson's strong market presence and diverse product portfolio make it a formidable competitor for Bayer.
2. Pfizer Inc. (PFE): Another major US pharmaceutical firm, Pfizer is Bayer's biggest competitor in the area of consumer healthcare products such as over-the-counter medications, vitamins, and supplements. Pfizer also competes with Bayer's pharmaceutical products, especially in the areas of oncology and vaccines.
3. Novartis AG (NVS): Based in Switzerland, Novartis is a global leader in the pharmaceutical and biotech industries. It competes with Bayer in several areas, including cardiovascular, oncology, and immunology drugs. Novartis's strong R pipeline and global reach make it a significant competitor for Bayer.
4. Roche Holding AG (RHHBY): Like Novartis, Roche is a Swiss-based company with a strong presence in the pharmaceutical and biotech industries. Roche's cancer treatments and diagnostic products compete with Bayer's oncology and hematology products. Roche is also a leading player in the field of personalized medicine, an area that Bayer is investing heavily in.
5. BASF SE (BASFY): As a German chemical company with a global footprint, BASF competes with Bayer in several areas of the life sciences industry. BASF's agrochemicals business, for instance, competes with Bayer's Crop Science division. Additionally, BASF's research and development efforts in the field of biotechnology have the potential to challenge Bayer in the long run.
Overall, Bayer faces tough competition from established industry players across its various business segments. The company's ability to innovate, effectively market its products, and manage its costs will be critical for maintaining its market position and facing off against these competitors.
Financial data and news for Bayer
sharewise wants to provide you with the best news and tools for Bayer, so we directly link to the best financial data sources.
Financials
News
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1)
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic